ReviewViruses2020
Plant-Based Vaccines: The Way Ahead?
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Plant-based production of monoclonal antibodies for rapid detection of Papaya ringspot virus.Physiology and molecular biology of plants : an international journal of functional plant biology · 2025Article
- Isolation and Transfection of Nicotiana benthamiana Mesophyll Protoplasts.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.Heliyon · 2024Review
- A multi-omic Nicotiana benthamiana resource for fundamental research and biotechnology.Nature plants · 2023Article
- Review
- Rescue of the first alphanucleorhabdovirus entirely from cloned complementary DNA: An efficient vector for systemic expression of foreign genes in maize and insect vectors.Molecular plant pathology · 2023Article
- Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases.Pharmaceutics · 2023Review
- Efficient expression of fusion human epidermal growth factor in tobacco chloroplasts.BMC biotechnology · 2023Article
- Plant-made vaccines against viral diseases in humans and farm animals.Frontiers in plant science · 2023Review
- Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.Journal of medical virology · 2022Article
- Improving Protein Quantity and Quality-The Next Level of Plant Molecular Farming.International journal of molecular sciences · 2022Review
- Plant-Derived Recombinant Vaccines against Zoonotic Viruses.Life (Basel, Switzerland) · 2022Review
- Directed Biosynthesis of New to Nature Alkaloids in a HeterologousFrontiers in plant science · 2022Article
- A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques.Frontiers in plant science · 2022Article
- Global Innovation Trends for Plant-Based Vaccines Production: A Patent Analysis.Plants (Basel, Switzerland) · 2021Article
- Transient protein expression systems in plants and their applications.Plant biotechnology (Tokyo, Japan) · 2021Article
- Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.Vaccines · 2021Review
- Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines.Plants (Basel, Switzerland) · 2021Review
- Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice.Vaccines · 2021Article
- A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development.Pathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Severe virus outbreaks are occurring more often and spreading faster and further than ever. Preparedness plans based on lessons learned from past epidemics can guide behavioral and pharmacological interventions to contain and treat emergent diseases. Although conventional biologics production systems can meet the pharmaceutical needs of a community at homeostasis, the COVID-19 pandemic has created an abrupt rise in demand for vaccines and therapeutics that highlight the gaps in this supply chain's ability to quickly develop and produce biologics in emergency situations given a short lead time. Considering the projected requirements for COVID-19 vaccines and the necessity for expedited large scale manufacture the capabilities of current biologics production systems should be surveyed to determine their applicability to pandemic preparedness. Plant-based biologics production systems have progressed to a state of commercial viability in the past 30 years with the capacity for production of complex, glycosylated, "mammalian compatible" molecules in a system with comparatively low production costs, high scalability, and production flexibility. Continued research drives the expansion of plant virus-based tools for harnessing the full production capacity from the plant biomass in transient systems. Here, we present an overview of vaccine production systems with a focus on plant-based production systems and their potential role as "first responders" in emergency pandemic situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.